Aktienanalyse zu Phathom Pharmaceuticals Inc (PHAT)PHATPhathom Pharmaceuticals Inc

Phathom Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the commercialization and development of novel treatments for gastrointestinal diseases. It has in-licensed the exclusive rights to vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB) for the United States (U.S.), Europe and Canada. PCABs are a novel class of molecules that block acid secretion in the stomach. The Company markets vonoprazan in the U.S. as VOQUEZNA (vonoprazan) tablets for the relief of heartburn associated with non-erosive gastroesophageal reflux disease (Non-Erosive GERD) in adults, the healing and maintenance of healing of Erosive GERD in adults and relief of associated heartburn, and as part of VOQUEZNA DUAL PAK (vonoprazan tablets, amoxicillin capsules) and VOQUEZNA TRIPLE PAK (vonoprazan tablets, amoxicillin capsules, clarithromycin tablets) for the treatment of H. pylori infection in adults. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Phathom Pharmaceuticals (PHAT) is currently trading at $6.92, which is significantly below the average analyst price target of $20. However, the stock has a low RSI of 39.876, indicating it is nearing oversold territory, but it has also experienced a year-to-date decline of 55.95%. The company's recent revenue growth of 88% year-over-year in Q2, reaching $74.3 million, shows potential for recovery. The main risk is the lowered 2026 revenue guidance of $310 million to $325 million, which may impact investor confidence.